Integer Holdings Reports Strong Start to 2025

Integer Holdings ( (ITGR) ) has released its Q1 earnings. Here is a breakdown of the information Integer Holdings presented to its investors.

Integer Holdings Corporation is a leading medical device contract development and manufacturing organization, primarily serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. The company is known for its innovative and high-quality products, partnering with medical device companies and OEMs to enhance patient care globally.

Integer Holdings Corporation reported a robust start to 2025, with first-quarter sales reaching $437 million, a 7% increase compared to the same period last year. The company has also raised its adjusted EPS outlook for the year, reflecting strong financial performance and strategic growth initiatives.

Key financial highlights include a 14% increase in non-GAAP adjusted operating income to $71 million and a 19% rise in non-GAAP adjusted net income to $46 million. The company’s Cardio & Vascular segment saw a significant 17% sales increase, driven by new product launches and strategic acquisitions. However, GAAP income from continuing operations showed a loss due to debt conversion inducement expenses.

Despite the challenges, Integer Holdings remains optimistic about its growth trajectory, maintaining a sales growth expectation of 8% to 10% for 2025. The company also anticipates a reduction in interest expenses due to its recent convertible notes offering, which is expected to enhance financial flexibility.

Looking ahead, Integer Holdings is poised to continue its strategic focus on innovation and market expansion. The management’s outlook suggests confidence in achieving the projected sales and income growth, supported by ongoing product development and operational efficiencies.